Everything below concerns Reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-23. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
=== Eating Disorder === To address the underlying eating disorder psychosocial interventions such as cognitive behavioral therapy, motivational therapy, problem-solving therapy, coping skills training, and family behavior therapy have all been shown to improve treatment adherence and achieve good glycemic control. It has been observed that addressing psychological needs improves HbA1c by 0.5%–1% in adults with T2DM. Useful therapies may involve cognitive behavioral therapy. Cognitive behavioral therapy focuses on changing unhealthy thinking surrounding the use of insulin. Family involvement and family therapy is helpful for long-term maintenance of good behaviors with taking insulin. A positive mindset to recovery, and connection with others who have experienced diabulimia, increases the probability of successful recovery.
The Sue Golding Graduate Division was established in 1957 to offer Doctor of Philosophy (PhD) degrees in biomedical science. In 1963, Einstein established its Department of Genetics, the first at any at any medical school; the coursework it offered was possibly the first formal medical curriculum on genetics. The following year, the Medical Scientist Training Program (MSTP), a combined MD/PhD program, was established. The first successful coronary artery bypass surgery was performed in 1960 at Einstein by a team led by Robert H. Goetz; the procedure has been described in The Annals of Thoracic Surgery as "one of the most significant surgical achievements of the 20th century". In 1966, the school completed a 375-bed private teaching hospital—now known as the Jack D. Weiler Hospital—with New York City Mayor John Lindsay presiding over its opening. The Ullmann Research Center for Health Sciences, a 12-story facility, opened in 1964. The following year, the Joseph P. Kennedy Jr. Foundation donated $1.45 million to Einstein to establish a center to study human development and mental disabilities. The center, named for Rose F. Kennedy, opened with 200 staff scientists in 1970. Also that year, the college began construction on the 15-story Charles C. and Beulah Bassine Educational Center devoted to public health. Beginning in 1971, aided by a five-year, $12,157,000 federal grant, the college experimented with a 3-year MD degree pathway and increased class sizes.
Finasteride/latanoprost/minoxidil (developmental code name TH-07 or TH07) is a topical combination drug which is under development for the treatment of alopecia (hair loss). It is specifically a combination of finasteride (Propecia) (0.1%), a 5α-reductase inhibitor (5α-RI); latanoprost (Xalatan) (0.03%), a prostaglandin F2α analogue and prostaglandin F receptor agonist; and minoxidil (Rogaine) (5%), a KATP potassium channel opener. All three of these drugs have individually been shown to stimulate hair growth in the setting of alopecia, and both finasteride and minoxidil are approved and widely used for treatment of alopecia. Finasteride/latanoprost/minoxidil is under development by Triple Hair. As of December 2023, the drug is in phase 2 clinical trials.
Sources: en.wikipedia.org
Lendemeriella aureopruinosa is a species of crustose lichen in the family Teloschistaceae. Found in the Russian Far East, it was formally described as a new species in 2021 by Ivan Frolov, Jan Vondrák, Ulf Arup, Liudmila Konoreva, and Sergey Chesnokov, Lidia Yakovchenko, and Evgeny Davydov. The type specimen was collected on the banks of River Bes-Yuryakh (Yllymakh, Republic of Sakha); here it was found growing on siliceous outcrops in a forest comprising largely birch, alder, and larch trees. The thallus of the lichen ranges in form from an inconspicuous grey film to a more well-developed crust or areoles. Its apothecia measure 0.3–0.6 mm in diameter and have a dark-orange to brick-red coloured disc. Secondary chemicals detected in the lichen (using high-performance liquid chromatography) include parietin, parietinic acid, emodin, teloschistin, and fallacinal. The specific epithet aureopruinosa refers to the bright gold-coloured pruina that is found on young apothecia.
MALDI-TOF spectra are often used for the identification of microorganisms such as bacteria or fungi. A portion of a colony of the microbe in question is placed onto the sample target and overlaid with matrix. The mass spectra of expressed proteins generated are analyzed by dedicated software and compared with stored profiles for species determination in what is known as biotyping. It offers benefits to other immunological or biochemical procedures and has become a common method for species identification in clinical microbiological laboratories. Benefits of high resolution MALDI-MS performed on a Fourier transform ion cyclotron resonance mass spectrometry (also known as FT-MS) have been demonstrated for typing and subtyping viruses though single ion detection known as proteotyping, with a particular focus on influenza viruses. One main advantage over other microbiological identification methods is its ability to rapidly and reliably identify, at low cost, a wide variety of microorganisms directly from the selective medium used to isolate them. The absence of the need to purify the suspect or "presumptive" colony allows for a much faster turn-around times. For example, it has been demonstrated that MALDI-TOF can be used to detect bacteria directly from blood cultures. Another advantage is the potential to predict antibiotic susceptibility of bacteria. A single mass spectral peak can predict methicillin resistance of Staphylococcus aureus.
=== Amino acid biosynthesis === All amino acids are formed from intermediates in the catabolic processes of glycolysis, the citric acid cycle, or the pentose phosphate pathway. From glycolysis, glucose 6-phosphate is a precursor for histidine; 3-phosphoglycerate is a precursor for glycine and cysteine; phosphoenol pyruvate, combined with the 3-phosphoglycerate-derivative erythrose 4-phosphate, forms tryptophan, phenylalanine, and tyrosine; and pyruvate is a precursor for alanine, valine, leucine, and isoleucine. From the citric acid cycle, α-ketoglutarate is converted into glutamate and subsequently glutamine, proline, and arginine; and oxaloacetate is converted into aspartate and subsequently asparagine, methionine, threonine, and lysine.
Sources: en.wikipedia.org
Initially, this development was not regarded by the medical profession as a clinically meaningful development. However, by 1996, the advent of insulin analogues which had vastly improved absorption, distribution, metabolism, and excretion (ADME) characteristics which were clinically meaningful based on this early biotechnology development. In 2005, a new drug to treat type 2 diabetes, derived from the Gila monster, was approved by the Food and Drug Administration. The venom of the lizard contains exendin 4, which triggers one of the insulin-releasing pathways.
=== Fruit and seed === The fruit develops from the ovary of the plant after fertilization, its flesh comprising the pericarp walls. The fruit contains locules, hollow spaces full of seeds. These vary among cultivated varieties. Some smaller varieties have two locules; globe-shaped varieties typically have three to five; beefsteak tomatoes have a great number of small locules; and plum tomatoes have very few, very small locules. The fruit contains lycopene that produces a red colour when ripe to attract animals that eat and disperse them elsewhere. However, not all tomatoes have same levels of lycopene; so not all of them have the same red colour when they ripe. Yellow tomatoes have levels of delta-carotene and lutein higher than lycopene, orange tomatoes have higher levels of beta-carotene and prolycopene. For propagation, the seeds need to come from a mature fruit, and must be lightly fermented to remove the gelatinous outer coating and then dried before use. The tomato has a mutualistic relationship with arbuscular mycorrhizal fungi such as Rhizophagus irregularis. Scientists use the tomato as a model species for investigating such symbioses.
Type I-minus is capable of manipulating objects on the scale of itself: building structures, mining, joining and breaking solids; Type II-minus is capable of manipulating genes and altering the development of living things, transplanting or replacing parts of themselves, reading and manipulating their genetic code; Type III-minus is capable of manipulating molecules and molecular bonds, creating new materials; Type IV-minus is capable of manipulating individual atoms, creating nanotechnology at the atomic level, and creating complex forms of artificial life; Type V-minus is capable of manipulating the atomic nucleus and engineering the nucleons that compose it; Type VI-minus is capable of manipulating the most elementary particles of matter (quarks and leptons) to create organized complexity among populations of elementary particles; Type Omega-minus is capable of manipulating the fundamental structure of space and time. In Impossibility: The Limits of Science and the Science of Limits (1998), Barrow proposes a scale ranging from "BI" to "BVI", with an ultimate stage he calls "BΩ", the former characterized by the possibility of manipulating one's environment, while the latter allows for the modification of spacetime.
== Side effects == Side effects are similar to other prostaglandin analogs applied to the eye. The most common one is conjunctival hyperemia, which occurs in more than 10% of patients. Other effects include blurred vision, eye and eyelid redness, eye burning or other discomfort, and permanent darkening of the iris to brown. Occasional adverse effects (in less than 1% of patients) are headache and nausea. Some side effects are specific to the cosmetic formulation, which is applied to the skin at the base of the eyelash rather than instilled into the eye. These include infection if the one-time applicators are reused, and darkening of the eyelid or of the area beneath the eye. Research suggests that wiping the eye with an absorbent pad after the administration of eye drops can result in shorter eyelashes and a lesser chance of hyperpigmentation in the eyelid, compared to not wiping off excess fluid.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.